{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:11:14Z","timestamp":1759565474384},"reference-count":31,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2018]]},"DOI":"10.1536\/ihj.17-082","type":"journal-article","created":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T17:14:39Z","timestamp":1518542079000},"page":"272-278","source":"Crossref","is-referenced-by-count":4,"title":["Decreased Serum Relaxin-2 Is Correlated with Impaired Islet \u03b2-Cell Function in Patients with Unstable Angina and Abnormal Glucose Metabolism"],"prefix":"10.1536","volume":"59","author":[{"given":"Xiangyu","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Cardiology, Beijing Friendship Hospital, Capital Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongwei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Beijing Friendship Hospital, Capital Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Beijing Friendship Hospital, Capital Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Beijing Friendship Hospital, Capital Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Samuel CS, Hewitson TD, Zhang Y, <i>et al<\/i>. Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy. Endocrinology 2008; 149: 3286-93.","DOI":"10.1210\/en.2008-0250"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Perreault L, Temprosa M, Mather KJ, <i>et al<\/i>. Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program outcomes study. Diabetes Care 2014; 37: 2622-31.","DOI":"10.2337\/dc14-0656"},{"key":"3","unstructured":"3. Ferrannini E, Gastaldelli A, Iozzo P. Pathophysiology of prediabetes. Med Clin North Am 2011; 95: 327-39."},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death? Science 2005; 307: 380-4.","DOI":"10.1126\/science.1104345"},{"key":"5","unstructured":"5. Cagliyan CE, Kirim S, Turkmen S, <i>et al<\/i>. Cardiac diastolic function is impaired at rest and worsens with exercise in otherwise healthy individuals with insulin resistance. Int Heart J 2015; 56: 345-8."},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998; 21: 2191-2.","DOI":"10.2337\/diacare.21.12.2191"},{"key":"7","unstructured":"7. Efird JT, Choi YM, Davies SW, <i>et al<\/i>. Potential for improved glycemic control with dietary momordica charantia in patients with insulin resistance and pre-diabetes. Int J Environ Res Public Health 2014; 11: 2328-45."},{"key":"8","unstructured":"8. Milman S, Crandall JP. Mechanisms of vascular complications in prediabetes. Med Clin North Am 2011; 95: 309-25."},{"key":"9","unstructured":"9. Kanat M, DeFronzo RA, Abdul-Ghani MA. Treatment of prediabetes. World J Diabetes 2015; 6: 1207-22."},{"key":"10","unstructured":"10. Ikeda N, Hara H, Hiroi Y. Ability of 1,5-Anhydro-d-glucitol values to predict coronary artery disease in a non-diabetic population. Int Heart J 2015; 56: 587-91."},{"key":"11","unstructured":"11. Shah AS, Gao Z, Urbina EM, <i>et al<\/i>. Pre-diabetes: The effects on arterial thickness and stiffness in obese youth. J Clin Endocrinol Metab 2014; 99: 1037-43."},{"key":"12","unstructured":"12. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 2010; 55: 1310-7."},{"key":"13","unstructured":"13. Whittaker PG, Edwards JR, Randolph C, <i>et al<\/i>. Abnormal relaxin secretion during pregnancy in women with type 1 diabetes. Exp Biol Med (Maywood) 2003; 228: 33-40."},{"key":"14","unstructured":"14. Sch\u00f6ndorf T, L\u00fcbben G, Hoopmann M, <i>et al<\/i>. Relaxin expression correlates significantly with serum fibrinogen variation in response to antidiabetic treatment in women with type 2 diabetes mellitus. Gynecol Endocrinol 2007; 23: 356-60."},{"key":"15","unstructured":"15. Shabanpoor F, Separovic F, Wade JD. The human insulin superfamily of polypeptide hormones. Vitam Horm 2009; 80: 1-31."},{"key":"16","unstructured":"16. Smith CM, Walker AW, Hosken IT, <i>et al<\/i>. Relaxin-3\/RXFP3 networks: an emerging target for the treatment of depression and other neuropsychiatric diseases? Front Pharmacol 2014; 5: 46."},{"key":"17","unstructured":"17. Samuel CS, Hewitson TD. Relaxin in cardiovascular and renal disease. Kidney Int 2006; 69: 1498-502."},{"key":"18","unstructured":"18. Teichman SL, Unemori E, Teerlink JR, <i>et al<\/i>. Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep 2010; 7: 75-82."},{"key":"19","unstructured":"19. Perna AM, Masini E, Nistri S, <i>et al<\/i>. Human recombinant relaxin reduces heart injury and improves ventricular performance in a swine model of acute myocardial infarction. Ann N Y Acad Sci 2005; 1041: 431-3."},{"key":"20","unstructured":"20. Valle Raleigh J, Mauro AG, Devarakonda T, <i>et al<\/i>. Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia\/reperfusion injury via eNOS-dependent mechanism. Cardiovasc Res 2017; 10. pii: cvw246."},{"key":"21","unstructured":"21. Roffi M, Patrono C, Collet JP, <i>et al<\/i>. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 267-315."},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. American Diabetes Association. Standards of medical care-2013. Diabetes Care 2013; 36: S11-66.","DOI":"10.2337\/dc13-S011"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-95.","DOI":"10.2337\/diacare.27.6.1487"},{"key":"24","unstructured":"24. Zhang X, Zhu M, Zhao M, <i>et al<\/i>. The plasma levels of relaxin-2 and relaxin-3 in patients with diabetes. Clin Biochem 2013; 46: 1713-6."},{"key":"25","unstructured":"25. Wang P, Li HW, Wang YP, <i>et al<\/i>. Effects of recombinant human relaxin upon proliferation of cardiac fibroblast and synthesis of collagen under high glucose condition. J Endocrinol Invest 2009; 32: 242-7."},{"key":"26","unstructured":"26. Szepietowska B, Gorska M, Szelachowska M. Plasma relaxin concentration is related to beta-cell function and insulin sensitivity in women with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008; 79: e1-3."},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Bonner JS, Lantier L, Hocking KM, <i>et al<\/i>. Relaxin treatment reverses insulin resistance in mice fed a high-fat diet. Diabetes 2013; 62: 3251-60.","DOI":"10.2337\/db13-0033"},{"key":"28","unstructured":"28. Heringlake M, Kox T, Poeling J, <i>et al<\/i>. The effects of physical exercise on plasma levels of relaxin, NTproANP, and NTproBNP in patients with ischemic heart disease. Eur J Med Res 2009; 14: 106-12."},{"key":"29","unstructured":"29. Bani D, Bigazzi M. Relaxin as a Cardiovascular Drug: A Promise Kept. Curr Drug Saf 2011; 6: 324-8."},{"key":"30","unstructured":"30. Zhang J, Qi YF, Geng B, <i>et al<\/i>. Effect of relaxin on myocardial ischemia injury induced by isoproterenol. Peptides 2005; 26: 1632-9."},{"key":"31","unstructured":"31. Conrad KP. Unveiling the vasodilatory actions and mechanisms of relaxin. Hypertension 2010; 56: 2-9."}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/59\/2\/59_17-082\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,31]],"date-time":"2018-03-31T00:51:08Z","timestamp":1522457468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/59\/2\/59_17-082\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.17-082","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}